Document is current
Any future updates will be listed below
-
Authors
Howard, Alex https://orcid.org/0000-0002-4195-6821
Hughes, David M.
Green, Peter L. https://orcid.org/0000-0002-6279-3769
Velluva, Anoop
Gerada, Alessandro https://orcid.org/0000-0002-6743-4271
Maskell, Simon https://orcid.org/0000-0003-1917-2913
Buchan, Iain E. https://orcid.org/0000-0003-3392-1650
Hope, William https://orcid.org/0000-0001-6187-878X
-
Funding
Funding for this research was provided by:
Wellcome Trust (226691/Z/22/Z)
- License Information
-
More Information
Article History
Received: 1 June 2024
Accepted: 4 November 2024
First Online: 21 November 2024
Competing interests
: Alex Howard declares personal consulting work for Pfizer outside the submitted work, and a donation from Pfizer to the University of Liverpool for a public and professional engagement project outside the submitted work. Iain Buchan declares consulting fees via University of Liverpool from AstraZeneca outside the submitted work. William Hope holds or has recently held research grants with UKRI, EU (FP7, IMI-1, IMI-2), Wellcome, F2G, Spero Therapeutics, Antabio, Pfizer, Allecra, Bugworks, Phico Therapeutics, BioVersys, Global Antimicrobial Research and Development Partnership (GARDP). He is (or has recently been) a consultant for Appili Therapeutics, F2G, Spero Therapeutics, Pfizer, GSK, Phico Therapeutics, Pulmocide, and Mundipharma Research Ltd. He was a member of the Specialist Advisory Committee for GARDP (2020-2023), a member of the British Society for Antimicrobial Chemotherapy (BSAC) Breakpoint Committee (2020-2023), a member of Health Technology Appraisal (HTA) Prioritisation Committee for hospital care and was the Specialty National Co-lead for Infection for the National Institute of Health Research (NIHR) (2020-2024). The other authors declare no competing interests.
